COL3A1 promotes gastric cancer progression by activating PI3K/AKT signaling.
COL3A1 plays an oncogenic role in several types of cancer; however, the function of COL3A1 in gastric cancer (GC) remains unknown.
APA
Mao X, Li W, et al. (2026). COL3A1 promotes gastric cancer progression by activating PI3K/AKT signaling.. Cancer gene therapy. https://doi.org/10.1038/s41417-026-01011-0
MLA
Mao X, et al.. "COL3A1 promotes gastric cancer progression by activating PI3K/AKT signaling.." Cancer gene therapy, 2026.
PMID
41723290
Abstract
COL3A1 plays an oncogenic role in several types of cancer; however, the function of COL3A1 in gastric cancer (GC) remains unknown. The present study investigated the function and possible molecular mechanisms of COL3A1 in GC. The results showed that COL3A1 mRNA and protein were overexpressed in GC tissues and cells, and is associated with Immune microenvironment remodeling. High COL3A1 expression indicates poor prognosis. ESR1 transcriptionally elevates COL3A1 expression in GC. COL3A1-integrin α1 autocrine and paracrine axis promotes the proliferation, invasion, and angiogenesis of GC by activating PI3K-AKT signaling pathway. Targeting COL3A1 could significantly inhibit GC growth in vivo. Collectively, our findings indicated that COL3A1 could act as an oncogene in GC through regulating the PI3K-AKT signaling pathway.
같은 제1저자의 인용 많은 논문 (5)
- A Novel Way for Upper Eyelid Rejuvenation by Combination of Local Fat-Fascia-Muscle Flap Repositioning for Middle-Aged Asian Women.
- GLP-1 receptor agonist-SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes.
- The disparity and trend of childhood cancer burden in survival perspective: a systematic analysis for the global burden of disease 2021.
- Context-Dependent Dual Roles of the Plexin-B Family in Cancer Progression: Mechanisms and Therapeutic Implications.
- Correspondence to letter to the editor 2 on "Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study".